| This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing information was available at the meeting and is available in the links below. |
| Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com. |
Exploring predictors of response to anti-CGRP monoclonal antibodies: latest clinical evidence
From Head Start's Annual Meeting, June 2024
Explore the latest clinical data with Professor Cristina Tassorelli
Professor Cristina Tassorelli presents the latest clinical evidence on predictors of response to anti-CGRP monoclonal antibodies, focusing on four key components of migraine: genetics, biology, phenotype, and psychology.
Professor Tassorelli also introduces findings from the phase IV UNITE trial study,01 highlighting fremanezumab’s potential to reduce migraine symptoms and cumulative burden of the condition and associated depression.0203
Abbreviations
CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.
Discover more about Head Start's Annual MeetingPrescribing Information
References
-
Back to contents.
UNITE study protocol NCT04041284.
-
Back to contents.
Lipton RB, et al. Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.
-
Back to contents.
Lipton RB, et al. Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: results of the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.
This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.
Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.
Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events